(Q46358333)

English

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

chronic schizophrenia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Henrik Lublin

0 references

author name string

Henrik Lublin

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

Hans-Joachim Haug

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

Hannu Koponen

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

Thordur Sigmundsson

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

Stefan A Kolb

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

4 Pt 3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

710-718

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Pharmacological treatment of psychotic agitation

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Glucose intolerance with atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Olanzapine-associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

1 reference

https://api.crossref.org/works/10.1080%2F15622970802269589

21 January 2018

Identifiers

10.1080/15622970802269589

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803070

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46358333&oldid=2108001173"